This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) Rides on Innovation Amid Rising Costs
by Zacks Equity Research
Edwards Lifesciences (EW) expects to report underlying sales growth in the mid-single-digit range for 2022, banking on market growth and the adoption of premium technologies.
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
by Zacks Equity Research
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
Charles River (CRL) Benefits From Price Rise Amid FX Woe
by Zacks Equity Research
Charles River's (CRL) RMS growth prospects are high, courtesy of accelerating growth for research model services and research models.
QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China
by Zacks Equity Research
QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.
Here's Why Investors Should Retain STERIS (STE) Stock for Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE), led by strong segmental growth and the Cantel Medical acquisition.
Henry Schein (HSIC) Expands Dental Offerings With New Pact
by Zacks Equity Research
Henry Schein's (HSIC) latest deal expands its offering in several fast-growing product segments, including clinical software and oral surgery and orthodontic products.
Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy
by Zacks Equity Research
The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries
by Zacks Equity Research
Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.
STERIS (STE) Gains on New Orders, FX Impact Dents Growth
by Zacks Equity Research
STERIS (STE) is on track to achieve its stated goal of approximately $50 million of cost synergies in fiscal 2023.
Medtronic (MDT) Enrolls 1st Patient Trial for Hugo RAS System
by Zacks Equity Research
Medtronic's Hugo RAS system is designed to be used in Expand URO U.S. clinical trial study for urologic surgical procedures.
Syneos Health (SYNH) to Enhance Clinical Trials With New Pact
by Zacks Equity Research
Syneos Health's (SYNH) extended partnership is part of the company's commitment to bringing clinical trials closer to the patient.
Here's Why You Should Invest in IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) owing to strong international growth.
Reasons to Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
QIAGEN's (QGEN) Therascreen KRAS Kit Receives FDA Approval
by Zacks Equity Research
QIAGEN's (QGEN) therascreen-based companion diagnostic detects KRAS G12C, a genetic mutation that is one of the most common KRAS variations related to cancer.
IDEXX (IDXX) CAG Sales Growth Strong, Costs Continue to Rise
by Zacks Equity Research
IDEXX's (IDXX) international revenues are primarily aided by gains in CAG and Water businesses.
3 Reasons to Hold DexCom (DXCM) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about DexCom (DXCM) owing to its strong product portfolio.
Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails
by Zacks Equity Research
Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.
Here's Why You Should Retain Walgreens Boots (WBA) For Now
by Zacks Equity Research
Investors are optimistic about Walgreens Boots (WBA) led by strategic collaborations and noteworthy product launches.
Integra's (IART) SIA Buyout Widens Breast Reconstruction Scope
by Zacks Equity Research
With the acquisition, SIA's DuraSorb's resorbable synthetic technology is expected to strengthen Integra's (IART) plastic and reconstructive surgery portfolio.
Thermo Fisher (TMO) Expands Global Footprint With New Facility
by Zacks Equity Research
Thermo Fisher's (TMO) new facility in China is a strategic addition to the company's global pharma services network.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Improving margins buoy optimism.
Boston Scientific's (BSX) New Buyout to Expand Global Presence
by Zacks Equity Research
Boston Scientific's (BSX) new acquisition deal is expected to strengthen the company's presence in China.
HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.
Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay
by Zacks Equity Research
Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.